This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.
Study Type
OBSERVATIONAL
Enrollment
156
hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).
University Hospital St. Pölten
Sankt Pölten, Lower Austria, Austria
RECRUITINGOccurrence of any hepatic decompensation event (per patient)
Any (further) hepatic decompensation event (compound endpoint; Baveno VII definition; ascites, variceal bleeding, hepatic encephalopathy)
Time frame: 12 months
Number and type of individual decompensation events (per patient)
Time frame: 12 months
Number of hospital admissions (per patient)
Time frame: 12 months
Number of acute on chronic liver failure events (per patient)
EF-CLIF (European Association for the Study of the Liver - Chronic Liver Failure) definition, CLIF-C (chronic liver failure score) ACLF (acute on chronic liver failure) grading
Time frame: 12 months
Number of ICU (intensive care unit) admissions (per patient)
Time frame: 12 months
Development of hepatocellular cancer or cholangiocarcinoma (per patient)
Time frame: 12 months
Number of deaths
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.